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Abstract
Background: Magnetic resonance enterography (MRE) is an established tool to evaluate for changes associated
with inflammatory bowel disease (IBD), but has not been studied in sub-clinical IBD. We sought to evaluate the use
of MRE in children with spondyloarthritis (SpA), who are at risk of having sub-clinical gut inflammation.
Methods: Children with juvenile idiopathic arthritis (JIA) with evidence of intestinal inflammation as evidence by
an abnormal fecal calprotectin assay were offered MRE of their intestines. Flavored sports drink containing
polyethylene glycol 3350 was used as oral contrast. Glucagon was used to arrest peristalsis. Patients were imaged
in the prone position on a 1.5 T scanner. Heavily T2-weighted fat-suppressed coronal and axial images using
breath-hold technique were obtained, followed by post-gadolinium fat-suppressed T1-weighted gradient echo
images.
Results: We recruited five children with juvenile idiopathic arthritis (JIA); four had SpA, and one had poly-articular
JIA. All five had evidence of intestinal inflammation based upon a positive fecal calprotectin assay and successfully
completed the MRE. Three of the studies showed findings suggestive of IBD, including thickening and contrast
uptake at the terminal ileum (TI) in one child, contrast uptake of the distal ileum in another, and prominent vasa
recta and mesenteric lymph nodes in the third. The child with evidence of inflammatory changes at the TI
underwent colonoscopy, which revealed inflammatory bowel disease limited to the TI.
Conclusions: MRE can be used to evaluate for subclinical IBD in children with JIA. This protocol was safe and well-
tolerated, and identified mild changes in three of the subjects.
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Background
Approximately two-thirds of adults with spondyloarthri-
tis (SpA) have inflammatory intestinal changes similar
to those detected in inflammatory bowel disease (IBD)
[1]. Similar findings were reported in a small pediatric
study [2]. However, these studies used colonoscopy, an
expensive and invasive tool and thus one that is not
well suited for research studies. Studies using barium
swallow and sigmoidoscopy have identified sub-clinical
intestinal inflammation in lower percentages of SpA
patients, suggesting decreased sensitivity in that
population [3,4]. Computed tomography involves signifi-
cant amounts of radiation exposure, and ultrasound is
limited in some centers by operator-dependence [5].
However, one potential tool that could be used safely to
evaluate the intestines in children and adults with SpA
is magnetic resonance enterography (MRE).
MRE is an accepted tool to diagnose and monitor
IBD. Although it does not visualize early mucosal
changes such as aphthous ulcerations, MRE allows for
the detection of bowel wall thickening and enhance-
ment, as well as extramural complications of IBD,
including strictures, fistulas, sinus tracts, abscesses,
fibro-fatty proliferation, and lymphadenopathy [5-10].
Studies in adults and children have shown MRE to be
accurate in the diagnosis of IBD, distinguishing it from
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other causes of abdominal pain with sensitivity 82 - 96%
and specificity > 90% [11-15].
These studies raise the possibility that MRE may be of
benefit to screen for subclinical intestinal inflammation
in SpA patients. We previously recruited children with
enthesitis-related arthritis (ERA) and other subtypes of
juvenile idiopathic arthritis (JIA), and obtained measure-
ments of fecal calprotectin, a stool study that assesses
the presence of inflammation based on neutrophil-
derived proteins that are resistant to metabolic break-
down by intestinal bacteria and can assist in differentiat-
ing inflammatory from non- inflammatory states [16]. In
that study, we showed elevated fecal calprotectin levels
in ERA patients, as compared to children with other JIA
subtypes, as well as controls consisting of children with
unrelated connective tissue diseases and non-inflamma-
tory causes of joint pain [17]. A limitation of fecal cal-
protectin is that it does not provide any information as
to the location of the inflammation or the presence of
specific complications potentially associated with IBD.
Thus, to evaluate the anatomic location and extent of
sub-clinical intestinal inflammation in children poten-
tially at higher risk of intestinal inflammation, we per-
formed a sub-study of the above, offering MRE to JIA
patients with elevated fecal calprotectin levels.
Methods
Patients
This was a prospective sub-study of fecal calprotectin
levels among patients with JIA [17], diagnosed accord-
ing to the International League of Associations for
Rheumatology (ILAR) criteria [18]. Calprotectin levels
were measured via ELISA in a commercial laboratory
(ARUP, Salt Lake City, UT), with values < 50 micro-
grams/gm considered negative, 50 - 120 borderline, and
≥ 121 elevated. Inclusion criteria for the current study
were a fecal calprotectin level of at least 121 micro-
grams/gm obtained as part of that study. Exclusion cri-
teria were inability to cooperate with the procedure,
allergy to IV contrast, renal insufficiency, MRI incompa-
tible devices or implants, and pregnancy; in practice, the
only exclusion criteria applied was inability to undergo
MRI without sedation. There was no strict age cut-off,
although most children under age 8 or 9 would not be
expected to be able to undergo unsedated MRI. All of
the JIA patients with elevated fecal calprotectin levels (≥
121 micrograms/gm) who were potentially mature
enough to undergo MRI without sedation were invited
to do so; of the 8 who met the inclusion criteria, 5
agreed to participate. This study was approved by the
Institutional Review Board at the UT Southwestern
Medical Center. Informed consent was obtained from




Patients were NPO for six hours prior to the study. We
used one packet (17 gm) of polyethylene glycol 3350
(over the counter Miralax®) dissolved in a flavored com-
mercial sports beverage (Gatorade®) in order to increase
bowel wall distension. Over the course of 2.5 hours,
they were given a total volume of 1250 ml; one quarter
of the total volume was taken approximately every 30
minutes, with the final dose given 15 - 30 minutes prior
to the study. To inhibit bowel peristalsis, patients were
administered 0.5 mg glucagon IV at the onset of the
study; a second dose was given if the radiologist (MDR)
determined that there was motion artifact suggestive of
peristalsis.
MR examination
Patients were imaged in the prone position. Utilizing a
body surface coil an MRI exam was acquired on a GE
1.5 Tesla (Milwaukee, WI) MR scanner. To minimize
motion artifact, the patient was asked to hold his or her
breath during image acquisition, and as stated above,
bowel motion was reduced with the administration of
glucagon. Sequences and parameters are summarized in
Table 1. The precontrast images allowed visualization of
bowel wall thickening, mesenteric lymph nodes, and
prominent vasa recta. IV gadolinium, 0.1 mmole/kg
(max 10 mmole) of gadoteridol (Prohance; Bracco diag-
nostics) was then administered, and additional images




Nine subjects with JIA had elevated fecal calprotectin
levels. One was incapable of undergoing unsedated MRI,
and three declined to participate in the MRI study.
Thus, five patients agreed to participate, and all five
completed the study (Table 2). There were no obvious
differences between active joint count, disease duration,
or presence vs absence of gastroenterology symptoms
between the five who participated and the three who
did not (data not shown.) All five had JIA and had an
elevated fecal calprotectin level (median 249). Four had
ERA; one had poly-articular JIA. Only one (patient # 4)
had significant gastrointestinal symptoms, consisting of
abdominal pain and weight loss prior to treatment with
corticosteroids, although he was asymptomatic at the
time of the study.
MR enterography findings
Patients # 2 and 3 had normal studies (Figure 1.) Patient
1 revealed increased bowel wall thickness (4 mm; Figure
2A) and enhancement (2B) at the terminal ileum (TI).
Patient 4 showed multiple mesenteric lymph nodes and
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prominent vasa recta (Figure 3.) Patient 5 showed
increased contrast uptake at the distal ileum, without
thickening (Figure 4.) There was no obvious correlation
between the presence or type of bowel wall inflamma-
tion and the fecal calprotectin levels.
Safety
The study was tolerated without any serious adverse
events. Patient 1 had mild emesis after the second dose
of glucagon. No other adverse events were reported.
Patient follow-up
The patients were followed for a median of 9.6 months
(range 5.3 - 15) after the MRI. Patient 1 subsequently
developed abdominal pain and was therefore referred to
gastroenterology; 5 weeks after the MRE, he underwent
colonoscopy, which revealed non-specific inflammatory
changes limited to the TI, prompting a diagnosis of
IBD. His medical management was changed from eta-
nercept to adalimumab, in order to treat his underlying
bowel disease; he subsequently has had improvement in
arthritis, albeit still active at the final visit. Patient # 4
was referred to gastroenterology but never made the
appointment. Nevertheless, due to the presence of active
arthritis as well as acute anterior uveitis, he was also
started on adalimumab, with improvement in his arthri-
tis symptoms, but continued to have active arthritis at
the end of the follow-up period. None of the other
patients underwent changes in their medical manage-
ment and were doing well at the final follow-up.
Patients 2, 3, and 5 were not diagnosed with IBD or
other intestinal illnesses.
The primary implication of this study is in demon-
strating that MRE may be a tool with which investiga-
tors can evaluate for subtle inflammatory changes in
patients with SpA. The gold standard, ileocolonoscopy,
is invasive and expensive, and thus not well-suited for
research purposes. Fecal calprotectin levels are elevated
in children with SpA [17], but they do not provide spe-
cific anatomical information within the intestines, and it
appears that their levels can be increased nearly two-
fold by use of non-steroidal anti-inflammatory drugs
[19,20]. Likewise, wireless capsule endoscopy (WCE) can
identify subclinical changes in SpA patients [21]; how-
ever, WCE does not identify changes beyond the intest-
inal mucosa, and is limited by risk of obstruction.
This study also provides further exploration of the
connection between intestinal inflammation and SpA.
We have previously hypothesized that in children with
SpA, intestinal inflammation helps maintain peripheral
synovitis via mechanisms yet unclear [22]. However,
the extent of inflammation need not be extensive;
indeed, while the majority of patients with SpA have
intestinal inflammation [1], only a minority develop
frank IBD. Likewise, in our study, the MRI findings
were subtle, and none showed the extensive complica-
tions previously reported in IBD patients [9,10], and
thus none of the patients were diagnosed with IBD on
the basis of the MRI. Tumor necrosis factor (TNF)
inhibitors differ in their capacity to treat established
IBD, with etanercept less efficacious as compared to
some of the TNF monoclonal antagonists [23,24]. It
follows that they may also differ in their capacity to
treat sub-clinical intestinal inflammation, such as that
identified in this study. If it is indeed the case that
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MRI sequences used; the length of each of the sequences ranged from 12 -
45 seconds. FIESTA = fast imaging employing steady state acquisition, FS =
fat-suppressed, fSPGR = fast spoiled gradient recalled echo, LAVA = liver
acquisition with volume acceleration, SSFSE = single shot fast spin echo, T2w
= T2-weighted
Table 2 Study patients
Patient # Dx Age/sex Disease duration (months) Fecal calprotectin* Medication use
1 ERA 10.8/M 15 231 MTX, ETA
2 ERA 16.1/M 37 249 None
3 pJIA 11.5/F 118 678 NSAID, MTX
4 ERA 10.9/M 11 310 NSAID, PRED, MTX
5 ERA 14.1/M 12 171 ETA
* Micrograms/gm of stool. Normal < 121. Abbreviations: ERA = enthesitis-related arthritis, ETA = etanercept, MTX = methotrexate, NSAID = non-steroidal anti-
inflammatory drugs, pJIA = poly-articular juvenile idiopathic arthritis, PRED = prednisone.
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sub-clinical intestinal inflammation helps maintain per-
ipheral arthritis in SpA, long-lasting remission may not
be possible in the absence of control of this intestinal
inflammation. Indeed, registry data indicates that suc-
cessful withdrawal of etanercept in children with ERA
is rare [25].
This study has several limitations. The sample size was
small, there was no control population, and there was
no gold standard study performed. Nevertheless, we
believe that these findings are specific and meaningful;
two of the patients had changes in the distal ileum, a
common site of inflammation in IBD [26], and in one,
colonoscopy confirmed inflammation at that location.
Conclusions
Magnetic resonance enterography identified subclini-
cal intestinal inflammation in three children with
spondyloarthritis. Future studies should prospectively
screen newly-diagnosed children with ERA for
A
B
Figure 1 Normal bowel. Axial T1 fSPGR with fat saturation post
contrast at the area of the distal ileum in 16 yo male with ERA
(patient 2); no bowel thickening or contrast uptake is evident a.
Coronal 2D FIESTA (pre-contrast image) in 11 yo female with poly-
articular JIA, with a normal TI indicated by the arrow (patient 3) b.
A
B
Figure 2 10 yo male with ERA (patient 1). Coronal 2D FIESTA
with fat saturation (pre-contrast) showing thickening at the TI
(arrow) a. Axial T1 fSPGR with fat saturation post-contrast showing
enhancement at the terminal ileum (arrow) b.
Figure 3 Another 10 yo male with ERA (Patient 4). Coronal 2D
FIESTA (pre-contrast) showing prominent vasa recta (large arrow)
and mesenteric lymph nodes (small arrows). The TI is not visualized
on this sequence, and was normal in this patient (not shown).
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intestinal inflammation with tools such as fecal cal-
protectin or MRE and evaluate whether or not the
presence of such inflammation predicts response to
anti-TNF therapy or ability to be withdrawn success-
fully from such therapy.
List of abbreviations used
ERA: enthesitis-related arthritis; FIESTA: fast imaging employing steady state
acquisition; fSPRG: fast spoiled gradient recalled echo; IBD: inflammatory
bowel disease; JIA: juvenile idiopathic arthritis; LAVA: liver acquisition with
volume acceleration; MRE: magnetic resonance enterography; SpA:
spondyloarthritis; TI: terminal ileum.
Acknowledgements
Dr. Stoll was supported by Grant Number UL1RR024982, titled, “North and
Central Texas Clinical and Translational Science Initiative” (Milton Packer, M.
D., PI) from the National Center for Research Resources (NCRR), a
component of the National Institutes of Health (NIH) and NIH Roadmap for
Medical Research, and its contents are solely the responsibility of the
authors and do not necessarily represent the official view of the NCRR or
NIH. Information on NCRR is available at http://www.ncrr.nih.gov/.
Author details
1UT Southwestern Medical Center/Department of Pediatrics/5323 Harry Hines
Boulevard/Dallas, TX 75390-9063, USA. 2Texas Scottish Rite Hospital for
Children/Department of Rheumatology/2222 Welborn Street/Dallas, TX
75219, USA. 3Dr. Stoll: University of Alabama at Birmingham/Department of
Pediatrics/Children’s Park Place/1601 4th Ave S./Suite 210/Birmingham, AL
35233, USA. 4Texas Scottish Rite Hospital for Children/Department of
Radiology/2222 Welborn Street/Dallas, TX 75219, USA.
Authors’ contributions
MS - study design, patient recruitment, manuscript preparation; AP - data
analysis, manuscript review; MP - study design; MDR - study design,
interpretation of MR images, manuscript preparation. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 October 2011 Accepted: 8 February 2012
Published: 8 February 2012
References
1. Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M: Gut
inflammation in the spondyloarthropathies: clinical, radiologic, biologic
and genetic features in relation to the type of histology. A prospective
study. J Rheumatol 1991, 18(10):1542-51.
2. Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, Maertens M,
Joos R: Gut inflammation in children with late onset pauciarticular
juvenile chronic arthritis and evolution to adult spondyloarthropathy–a
prospective study. J Rheumatol 1993, 20(9):1567-72.
3. McBride JA, King MJ, Baikie AG, Crean GP, Sircus W: Ankylosing Spondylitis
and Chronic Inflammatory Diseases of the Intestines. Br Med J 1963,
2(5355):483-6.
4. Costello PB, Alea JA, Kennedy AC, McCluskey RT, Green FA: Prevalence of
occult inflammatory bowel disease in ankylosing spondylitis. Ann Rheum
Dis 1980, 39(5):453-6.
5. Tolan DJ, Greenhalgh R, Zealley IA, Halligan S, Taylor SA: MR enterographic
manifestations of small bowel Crohn disease. Radiographics 2010,
30(2):367-84.
6. Bernstein CN, Greenberg H, Boult I, Chubey S, Leblanc C, Ryner L: A
prospective comparison study of MRI versus small bowel follow-through
in recurrent Crohn’s disease. Am J Gastroenterol 2005, 100(11):2493-502.
7. Mann EH: Inflammatory bowel disease: imaging of the pediatric patient.
Semin Roentgenol 2008, 43(1):29-38.
8. Lin MF, Narra V: Developing role of magnetic resonance imaging in
Crohn’s disease. Curr Opin Gastroenterol 2008, 24(2):135-40.
9. Frokjaer JB, Larsen E, Steffensen E, Nielsen AH, Drewes AM: Magnetic
resonance imaging of the small bowel in Crohn’s disease. Scand J
Gastroenterol 2005, 40(7):832-42.
10. Torkzad MR, Ullberg U, Nystrom N, Blomqvist L, Hellstrom P, Fagerberg UL:
Manifestations of small bowel disease in pediatric Crohn’s disease on
magnetic resonance enterography. Inflamm Bowel Dis 2011.
11. Laghi A, Borrelli O, Paolantonio P, Dito L, Buena de Mesquita M,
Falconieri P, Cucchiara S: Contrast enhanced magnetic resonance
imaging of the terminal ileum in children with Crohn’s disease. Gut
2003, 52(3):393-7.
12. Darbari A, Sena L, Argani P, Oliva-Hemker JM, Thompson R, Cuffari C:
Gadolinium-enhanced magnetic resonance imaging: a useful
radiological tool in diagnosing pediatric IBD. Inflamm Bowel Dis 2004,
10(2):67-72.
13. Borthne AS, Abdelnoor M, Rugtveit J, Perminow G, Reiseter T, Klow NE:
Bowel magnetic resonance imaging of pediatric patients with oral
mannitol MRI compared to endoscopy and intestinal ultrasound. Eur
Radiol 2006, 16(1):207-14.
14. Magnano G, Granata C, Barabino A, Magnaguagno F, Rossi U, Calevo MG,
Toma P: Polyethylene glycol and contrast-enhanced MRI of Crohn’s
disease in children: preliminary experience. Pediatr Radiol 2003,
33(6):385-91.
15. Horsthuis K, Bipat S, Bennink RJ, Stoker J: Inflammatory bowel disease
diagnosed with US, MR, scintigraphy, and CT: meta-analysis of
prospective studies. Radiology 2008, 247(1):64-79.
16. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S,
Foster R, Sherwood R, Fagerhol M, Bjarnason I: A simple method for
assessing intestinal inflammation in Crohn’s disease. Gut 2000,
47(4):506-13.
17. Stoll ML, Punaro M, Patel AS: Fecal Calprotectin in Children with the
Enthesitis-related Arthritis Subtype of Juvenile Idiopathic Arthritis. J
Rheumatol 2011, 38(10):2274-5.
18. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al:
International League of Associations for Rheumatology classification of
juvenile idiopathic arthritis: second revision, Edmonton, 2001. J
Rheumatol 2004, 31(2):390-2.
19. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A,
Bjarnason I: High prevalence of NSAID enteropathy as shown by a simple
faecal test. Gut 1999, 45(3):362-6.
20. Meling TR, Aabakken L, Roseth A, Osnes M: Faecal calprotectin shedding
after short-term treatment with non-steroidal anti-inflammatory drugs.
Scand J Gastroenterol 1996, 31(4):339-44.
21. Eliakim R, Karban A, Markovits D, Bardan E, Bar-Meir S, Abramowich D,
Scapa E: Comparison of capsule endoscopy with ileocolonoscopy for
detecting small-bowel lesions in patients with seronegative
spondyloarthropathies. Endoscopy 2005, 37(12):1165-9.
Figure 4 14 yo male with ERA (Patient 5). Axial T1 fSPGR with fat
saturation post contrast showing abnormal enhancement at the
distal ileum (arrow). There was no obvious bowel wall thickening.
Stoll et al. Pediatric Rheumatology 2012, 10:6
http://www.ped-rheum.com/content/10/1/6
Page 5 of 6
22. Stoll ML: Interactions of the innate and adaptive arms of the immune
system in the pathogenesis of spondyloarthritis. Clin Exp Rheumatol 2011,
29(2):322-30.
23. Marzo-Ortega H, McGonagle D, O’Connor P, Emery P: Efficacy of
etanercept for treatment of Crohn’s related spondyloarthritis but not
colitis. Ann Rheum Dis 2003, 62(1):74-6.
24. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P: Efficacy
of biological therapies in inflammatory bowel disease: systematic review
and meta-analysis. Am J Gastroenterol 2011, 106(4):644-59, quiz 660.
25. Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP,
Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van
den Berg JM, van Rossum MA, van Suijlekom-Smit LW: Tumor necrosis
factor-blocking agents for children with enthesitis-related arthritis–data
from the dutch arthritis and biologicals in children register, 1999-2010. J
Rheumatol 2011, 38(10):2258-63.
26. Caprilli R: Why does Crohn’s disease usually occur in terminal ileum? J
Crohns Colitis 2008, 2(4):352-6.
doi:10.1186/1546-0096-10-6
Cite this article as: Stoll et al.: MR enterography to evaluate sub-clinical
intestinal inflammation in children with spondyloarthritis. Pediatric
Rheumatology 2012 10:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Stoll et al. Pediatric Rheumatology 2012, 10:6
http://www.ped-rheum.com/content/10/1/6
Page 6 of 6
